Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.
anthracyclines
breast cancer
hormone receptor
metastatic
non-pegylated liposomal doxorubicin
triple negative
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Sep 2021
01 Sep 2021
Historique:
received:
28
06
2021
revised:
27
08
2021
accepted:
31
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
11
9
2021
Statut:
epublish
Résumé
Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non-pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450-480 mg/m
Identifiants
pubmed: 34503231
pii: cancers13174421
doi: 10.3390/cancers13174421
pmc: PMC8430783
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005006
pubmed: 17054231
Clin Cancer Res. 2009 Jan 1;15(1):307-14
pubmed: 19118059
Hematol Oncol. 2020 Oct;38(4):478-486
pubmed: 32542788
BMC Cancer. 2018 Oct 25;18(1):1037
pubmed: 30359235
Anticancer Drugs. 2005 Jan;16(1):21-9
pubmed: 15613900
BMC Med. 2019 Jan 9;17(1):8
pubmed: 30621698
Cancer Res. 1986 May;46(5):2295-9
pubmed: 3697976
PLoS One. 2015 Jul 23;10(7):e0133569
pubmed: 26204517
Cancers (Basel). 2020 Nov 25;12(12):
pubmed: 33255658
Eur Heart J Cardiovasc Imaging. 2017 May 01;18(8):930-936
pubmed: 28379383
Front Oncol. 2019 Aug 13;9:759
pubmed: 31456944
Clin Pharmacokinet. 2003;42(5):419-36
pubmed: 12739982
Ann Oncol. 2011 Jan;22(1):74-79
pubmed: 20603435
Clin Breast Cancer. 2012 Oct;12(5):313-21
pubmed: 22728026
Br J Haematol. 2005 Dec;131(5):561-78
pubmed: 16351632
Front Cardiovasc Med. 2020 Mar 18;7:26
pubmed: 32258060
Int J Oncol. 2014 Nov;45(5):2137-42
pubmed: 25176223
J Clin Oncol. 1985 Jun;3(6):818-26
pubmed: 3859587
Cancer Treat Rev. 2016 Nov;50:129-141
pubmed: 27665540
Ann Oncol. 2014 Mar;25(3):592-598
pubmed: 24401928
Breast. 2013 Dec;22(6):1101-7
pubmed: 24074879
Cancer Chemother Pharmacol. 2009 Jul;64(2):401-6
pubmed: 19104816
Eur J Cancer. 2011 Nov;47(16):2396-402
pubmed: 21920729
J Cancer. 2014 Apr 25;5(6):398-405
pubmed: 24847380
Hematol Oncol. 2018 Feb;36(1):68-75
pubmed: 28524259
J Clin Oncol. 2005 Nov 1;23(31):7794-803
pubmed: 16172456
ESMO Open. 2021 Apr;6(2):100099
pubmed: 33819752
Ann Oncol. 2004 Oct;15(10):1527-34
pubmed: 15367414
Int J Mol Sci. 2019 Dec 18;21(1):
pubmed: 31861465
Future Oncol. 2020 Aug;16(22):1629-1637
pubmed: 32501121
Lancet Oncol. 2019 Oct;20(10):1360-1369
pubmed: 31494037
Ann Oncol. 2011 Feb;22(2):257-67
pubmed: 20956616
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
Sci Rep. 2020 Oct 28;10(1):18481
pubmed: 33116159
Eur J Cancer. 2011 Sep;47(14):2091-8
pubmed: 21665463
Ann Oncol. 2019 Oct 1;30(10):1674
pubmed: 31236598
J Clin Oncol. 2001 Mar 1;19(5):1444-54
pubmed: 11230490
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
Int J Breast Cancer. 2014;2014:984067
pubmed: 24527216
Eur J Cancer. 2021 May;149:134-152
pubmed: 33862496
Clin Cancer Res. 2010 Dec 1;16(23):5664-78
pubmed: 20829328
Crit Rev Oncol Hematol. 2011 Oct;80(1):160-70
pubmed: 21035352
J Clin Oncol. 2021 Nov 10;39(32):3541-3545
pubmed: 34406849
Ann Oncol. 2020 Dec;31(12):1623-1649
pubmed: 32979513
Cancer. 2002 Jan 1;94(1):25-36
pubmed: 11815957
Breast Cancer Res Treat. 2019 Apr;174(2):433-442
pubmed: 30536182
Breast. 2010 Oct;19(5):333-8
pubmed: 20185313
Breast. 2017 Feb;31:186-191
pubmed: 27886643
J Natl Compr Canc Netw. 2021 May 01;19(5):484-493
pubmed: 34794122
J Natl Cancer Inst. 2020 Nov 1;112(11):1089-1097
pubmed: 32407488
Syst Rev. 2017 Apr 12;6(1):79
pubmed: 28403893
Ann Oncol. 2005 Oct;16(10):1624-31
pubmed: 16030028
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
J Clin Oncol. 2009 Aug 1;27(22):3611-9
pubmed: 19470941
Ann Oncol. 2011 Feb;22(2):315-20
pubmed: 20693299
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Am J Clin Oncol. 1989 Feb;12(1):57-62
pubmed: 2643296
Int J Cardiol. 2017 May 15;235:147-153
pubmed: 28268088
J Clin Oncol. 2000 Sep;18(17):3115-24
pubmed: 10963640
J Clin Oncol. 1991 Dec;9(12):2148-52
pubmed: 1960557
J Clin Oncol. 2021 Dec 10;39(35):3938-3958
pubmed: 34324366
Circ Heart Fail. 2013 May;6(3):420-6
pubmed: 23425978